AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a more restrictive label ...
In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...
Scientists at Rutgers University-New Brunswick have discovered that exercise can activate special cells in the brain that ...
The Sacramento Metropolitan Chamber of Commerce recently held its 130th annual Dinner & Business Awards at the Hyatt Regency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback